Virax Biolabs Group (VRAX) Projected to Post Earnings on Saturday

Virax Biolabs Group (NASDAQ:VRAX) is projected to post its results before the market opens on Saturday, November 1st. Analysts expect Virax Biolabs Group to post earnings of ($0.34) per share for the quarter.

Virax Biolabs Group Stock Down 0.7%

Shares of Virax Biolabs Group stock opened at $0.59 on Friday. Virax Biolabs Group has a one year low of $0.52 and a one year high of $3.20. The business has a 50-day simple moving average of $0.62 and a 200 day simple moving average of $0.82.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Virax Biolabs Group in a research report on Tuesday, October 14th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.00.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.